Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cebranopadol - Tris Pharma

Next Previous
Drug Profile

Cebranopadol - Tris Pharma

Alternative Names: GRT-6005; PRK-101; TRN-228

Latest Information Update: 01 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Grunenthal
  • Developer Grunenthal; Park Therapeutics; Tris Pharma
  • Class Cyclohexylamines; Drug withdrawal therapies; Indoles; Opioid analgesics; Small molecules; Spiro compounds
  • Mechanism of Action Nociceptin receptor agonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer pain

Highest Development Phases

  • Phase III Acute pain; Back pain; Postoperative pain
  • Phase II Cancer pain; Neuropathic pain
  • Phase I Substance-related disorders
  • No development reported Pain

Most Recent Events

  • 22 Sep 2026 Adneuris Therapeutics initiates enrolment in a phase III trial for Acute pain in USA (NCT07845071)
  • 05 Aug 2026 Cebranopadol licensed to Maruishi Pharmaceutical in Japan and South Korea
  • 14 Jul 2026 Cebranopadol licensed to Zhejiang Conba Pharmaceutical in China, Hong Kong, Macau and Taiwan

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top